Molecular Mechanisms Regulating PIK3CA-induced Venous Malformations

Information

  • Research Project
  • 10211277
  • ApplicationId
    10211277
  • Core Project Number
    R01HL151679
  • Full Project Number
    1R01HL151679-01A1
  • Serial Number
    151679
  • FOA Number
    PA-20-185
  • Sub Project Id
  • Project Start Date
    6/10/2021 - 3 years ago
  • Project End Date
    5/31/2025 - 6 months from now
  • Program Officer Name
    GAO, YUNLING
  • Budget Start Date
    6/10/2021 - 3 years ago
  • Budget End Date
    5/31/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    6/10/2021 - 3 years ago
Organizations

Molecular Mechanisms Regulating PIK3CA-induced Venous Malformations

Summary PI3?-Kinase (PI3K) signaling is critical for proper angiogenesis, the development of new blood vessels. However, aberrant PI3K signaling is associated with a wide range of vascular malformations (VMs), including venous malformations which can arise from somatic activating mutations in PIK3CA. VMs are failures in proper endothelial cell development and differentiation giving rise to dysfunctional blood vessels that leave affected patients with significant morbidity and often disfigurement. Our long-term goal is to better understand the molecular etiology of vascular malformations with the hope of contributing novel approaches to the treatment of these conditions non-surgically. We have developed in vitro and in vivo models of PIK3CA-driven VMs and find that the mTORC1 axis may be a critical component of improper vascular morphogenesis. Our central hypothesis is that the mTORC1 axis is being regulated through a novel mechanism; the induction of the mTORC1 regulating protein RHEB. This proposal seeks to determine the role of RHEB in driving malformations arising from PIK3CA mutations and reveal molecular insights into the mechanisms by which RHEB/mTORC1 axis promotes the development of vascular malformations.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
    225001
  • Indirect Cost Amount
    141625
  • Total Cost
    366626
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    837
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NHLBI:366626\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    CDD
  • Study Section Name
    Cardiovascular Differentiation and Development Study Section
  • Organization Name
    ALBANY MEDICAL COLLEGE
  • Organization Department
    ANATOMY/CELL BIOLOGY
  • Organization DUNS
    190592162
  • Organization City
    ALBANY
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    122083479
  • Organization District
    UNITED STATES